Notably, these mutations can sustain oncogenic signaling and confer resistance to EGFR-targeted therapies, while ERBB2 amplification is linked to a non-inflammatory tumor microenvironment that may impact immunotherapy response.25 This evidence concerns the gene ERBB2 and neoplasm.